HAE vs. COO, XRAY, MMSI, NEOG, ICUI, QDEL, STAA, ATRI, CERS, and ANIK
Should you be buying Haemonetics stock or one of its competitors? The main competitors of Haemonetics include Cooper Companies (COO), DENTSPLY SIRONA (XRAY), Merit Medical Systems (MMSI), Neogen (NEOG), ICU Medical (ICUI), QuidelOrtho (QDEL), STAAR Surgical (STAA), Atrion (ATRI), Cerus (CERS), and Anika Therapeutics (ANIK). These companies are all part of the "health care supplies" industry.
Haemonetics (NYSE:HAE) and Cooper Companies (NASDAQ:COO) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, community ranking, earnings, valuation, risk and media sentiment.
Haemonetics currently has a consensus target price of $109.50, indicating a potential upside of 20.25%. Cooper Companies has a consensus target price of $111.78, indicating a potential upside of 19.92%. Given Haemonetics' higher possible upside, analysts plainly believe Haemonetics is more favorable than Cooper Companies.
Haemonetics has a beta of 0.29, suggesting that its stock price is 71% less volatile than the S&P 500. Comparatively, Cooper Companies has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500.
Cooper Companies has higher revenue and earnings than Haemonetics. Haemonetics is trading at a lower price-to-earnings ratio than Cooper Companies, indicating that it is currently the more affordable of the two stocks.
In the previous week, Cooper Companies had 13 more articles in the media than Haemonetics. MarketBeat recorded 20 mentions for Cooper Companies and 7 mentions for Haemonetics. Haemonetics' average media sentiment score of 0.69 beat Cooper Companies' score of 0.58 indicating that Haemonetics is being referred to more favorably in the media.
Cooper Companies received 227 more outperform votes than Haemonetics when rated by MarketBeat users. Likewise, 66.63% of users gave Cooper Companies an outperform vote while only 60.95% of users gave Haemonetics an outperform vote.
Cooper Companies has a net margin of 9.11% compared to Haemonetics' net margin of 8.98%. Haemonetics' return on equity of 22.25% beat Cooper Companies' return on equity.
99.7% of Haemonetics shares are owned by institutional investors. Comparatively, 24.4% of Cooper Companies shares are owned by institutional investors. 1.8% of Haemonetics shares are owned by insiders. Comparatively, 2.0% of Cooper Companies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Cooper Companies beats Haemonetics on 11 of the 17 factors compared between the two stocks.
Get Haemonetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HAE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HAE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Haemonetics Competitors List
Related Companies and Tools
